Antimicrobial Wound Dressings Patents: Who Leads 2026
- One filer, 52 records. The leading assignee alone accounts for a third of the 159 records in scope, and the top 5 combined reach 62.9%.
- A61L dominates claim language. 79.9% of records touch sterilising and disinfecting (A61L), against 18.9% for medicinal preparations (A61K) — most of the drafting activity sits on the delivery mechanism, not the active compound.
- Filing activity is still rising, not falling. 2021 to 2024 shows +100% growth (1 to 2 records for the tracked assignee), and 2025-2026 figures are undercounted because publication lags filing by about 18 months.
Filing growth compares 2021 (1 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 159 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks 159 published records filed between 2015 and 2026 that combine antimicrobial wound dressing or silver wound dressing terminology with a specific mechanism claim — silver release, iodine dressing chemistry, biofilm disruption, cytotoxicity balance, resistance concern, or dressing longevity. That combination narrows the field to documents that go beyond a generic antimicrobial claim and specify how the dressing behaves over time or against resistant organisms.
The technology splits along two axes: the delivery substrate (fibre, fabric, hydrogel, foam) and the antimicrobial mechanism (ionic silver, iodine complex, biofilm-targeting enzymes or surfactants). Filing activity concentrates heavily on the substrate and release-control side, classified under sterilising and disinfecting (A61L), while the therapeutic and biocide classifications carry a smaller, more specialised share of the corpus.
Filing trend and technology composition
Two views of the same 159-record corpus: how filing activity has moved year over year, and which IPC subclasses carry the claim language.
Filing trend
Filings peaked at 12 in 2018, and the tracked three-year window from 2021 to 2024 shows filing growth of +100% (1 to 2 records). The 2025 and 2026 figures should be read as still filling in, since publication typically lags filing by roughly 18 months — they are not evidence of a slowdown.
IPC technology composition
A61L (sterilising and disinfecting) appears in 79.9% of the 159 records, far ahead of A61K medicinal preparations (18.9%), A01N biocides (16.4%) and A61F implants (16.4%). Because a single record can carry several IPC classes, these shares sum to well over 100% — they describe overlap, not a partition of the corpus.
Shares are the percentage of the 159 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Antimicrobial Wound Dressings with Eureka
This page is one run against one query. Ask Eureka your own question about antimicrobial wound dressings and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
US20150297411A1 — Silver containing antimicrobial fibre, fabric and wound dressing and its method of manufacturing
Silver ions distributed evenly within or on the surface of an antibacterial fibre structure, with silver content held at 0.01-10 weight percent, enable continuous, long-term silver release for chronic wound treatment while preventing bacterial or microbial infection of the wound.Filed by Foshan United Medical Technologies Ltd., published 22 October 2015.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20110313383A1 | Wound dressing | 59 |
| 2 | US20120220981A1 | Transcutaneous Multimodal Delivery System (TMDS) | 56 |
| 3 | US20040202703A1 | Antimicrobial wound covering article | 40 |
| 4 | WO2019012069A1 | Antimicrobial or wound care materials, devices and uses | 34 |
| 5 | WO2011129759A1 | Antimicrobial gels | 29 |
| 6 | US20060062831A1 | Polymeric composite for use in wound management products | 27 |
| 7 | WO2017016974A1 | Absorbent antimicrobial wound dressings | 23 |
| 8 | US9089677B2 | Transcutaneous multimodal delivery system (TMDS) | 22 |
| 9 | US20120009275A1 | In-situ forming hydrogel wound dressings containing antimicrobial agents | 20 |
| 10 | US20160208430A1 | Cellulose Fibres | 19 |
Citation counts favour older filings that have had more time to accumulate citations inside this searched corpus — read them as a signal of influence on the field's claim language, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-outs from the corpus that matter more than the raw counts on their own.
Filing activity is concentrated at the top
The top 5 assignees combined account for 100 of the 159 records in scope — 62.9% of the field — and the top 10 extend that to 83.6%. A single leading assignee holds 52 records on its own. For a new entrant, this means the core silver-release and fibre-substrate claim space is already densely occupied by a small number of players.
Claims cluster on delivery, not on the active agent
A61L (sterilising and disinfecting) appears in nearly four out of five records, while A61K (medicinal preparations) sits at 18.9% and A01N (biocides) at 16.4%. The bulk of drafting effort is going into how the antimicrobial is held and released from the dressing substrate, rather than into new active compounds.
Activity is still rising, read with a caveat
The tracked three-year window shows growth from 1 to 2 records (+100%), and 2024 is the most recent year that can be treated as complete. Because publication lags filing by roughly 18 months, the apparent tail-off in 2025-2026 is an artefact of the data cut-off, not a real decline in filing.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to antimicrobial wound dressings, with the prior art for and against each one.
Who is filing, and where the gate sits
A small group of assignees holds most of the corpus, and co-filing activity is concentrated around one inventor cluster rather than spread across the field.
One assignee sets the pace
The leading assignee's 52 records represent close to a third of the entire 159-record corpus by itself, well ahead of the fifth-placed assignee's 8 and tenth-placed assignee's 5. Recent-year momentum for this group shows 0 filings in the latest tracked year across several of the top names, consistent with the 18-month publication lag rather than a pullback.
Co-filing clusters around one inventor group
Ten co-assignee pairs appear in the dataset, and the three strongest pairs all involve the same lead inventor paired with different collaborators at 7 shared records each. This points to a single active research group rather than a broad pattern of joint filing across the field.
Filing offices favour the US and EPO
The United States receives the largest share of filings at 38, followed by the European Patent Office at 34 and WIPO/PCT filings at 16. Australia, Canada and Germany each carry a smaller but non-trivial share, indicating deliberate multi-jurisdiction strategy among the leading filers rather than single-market protection.
| Assignee | Recent year | YoY |
|---|---|---|
| Molnlycke Health Care AB | 0 | -100% |
| Smith & Nephew plc | 0 | — |
| Speciality Fibers & Materials | 0 | — |
| Marquette University | 0 | — |
| INNOVOTECH | 0 | — |
| HIRT THOMAS | 0 | — |
| Covidien LP | 0 | — |
| Foshan United Medical Technologies Ltd. | 0 | — |
Where to take this analysis
The dataset points to a field with a dominant filer, a dense core claim area, and several thinner branches that have not yet attracted heavy filing.
Map the white space claims
Biofilm-disruption and cytotoxicity-balance mechanisms carry far fewer records than silver-release fibre claims, suggesting room for a first-filer position if the mechanism can be specified precisely.
Explore white space in EurekaWatch the concentrated leader
With 52 records held by one assignee, tracking that filer's newest applications is the fastest way to see where the core claim space is still expanding.
Track assignee activity in EurekaCheck freedom-to-operate against the cited core
The most-cited records in this corpus, several dating to the early 2010s, still anchor citation chains across newer filings and are worth a direct claim comparison before drafting.
Run a claim comparison in EurekaCommon questions on this landscape
One assignee holds 52 of the 159 records in this corpus, making it the clear leader by a wide margin over the rest of the ranked field. The top 5 assignees combined account for 62.9% of all records, and the top 10 reach 83.6%. Beyond the leading names, the ranking of 58 companies shows a long tail of assignees with only one or a handful of filings each, so the field is best described as concentrated at the top with a thin tail rather than evenly distributed.
The tracked three-year window from 2021 to 2024 shows filing growth of +100%, and 2024 is the most recent year in this dataset that can be treated as complete. Figures for 2025 and 2026 look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity. The historical peak so far was 2018, at 12 filings in a single year.
A61L, the sterilising-and-disinfecting classification, appears in 79.9% of the 159 records, making it by far the most common claim area. Medicinal preparations (A61K) and biocides (A01N) each cover under a fifth of records, and implant-related classifications (A61F) sit at a similar level. Because records often carry multiple IPC classes, most filings that mention delivery mechanisms also touch one or more of these secondary categories rather than sitting in a single class alone.
Relative to the dense core of silver-release fibre and fabric claims, mechanism-specific areas such as biofilm-disruption carriers, cytotoxicity-balanced dosing and iodine-complex slow-release matrices carry noticeably fewer records. Polymer-processing classifications like C08J cover only 6.9% of the corpus, suggesting formulation and processing routes are less crowded than the core substrate claims. A first filer specifying a precise release-control mechanism in one of these branches would be entering a less contested claim space than the general silver-fibre area.
No — high filing density in a claim area like A61L shows that space is already occupied, not that the underlying technology has stopped developing or that products built on it are widespread. Citation counts on the older, most-cited records in this corpus reflect the fact that older documents have had more time to accumulate citations, not that they remain the most commercially relevant today. Growth figures and filing counts should be read alongside product and regulatory data before drawing conclusions about market maturity.
Research Antimicrobial Wound Dressings in depth with Eureka
Go past this page: query the whole antimicrobial wound dressings corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.